NIPS Early Access Program

Recent recommendations from ACOG and other professional medical societies endorse cell-free DNA (cfDNA) analysis as the most sensitive and specific screening for common fetal aneuploidies, regardless of maternal risk. Such endorsements dramatically expand the addressable population of patients who may benefit from cfDNA-based NIPS. Yet, the past decade of NIPS offers only a single path to this screening.

Junoʼs NIPS solution simplifies sample collection and enables equitable access to high-quality genetic testing results – without the high cost, long lead times, and inconvenient phlebotomy requirements of traditional NIPS.

Questions? Comments? Let us know how we can help!